Drugs versus placebo for dysthymia (Q24187378)

Cochrane Database of Systematic Reviews

Europe PubMed Central

title

Drugs versus placebo for dysthymia (English)

0 references

0 references

2

Joanna Moncrieff

0 references

author name string

Mauricio Silva de Lima

series ordinal

1

0 references

Bernardo GO Soares

series ordinal

3

0 references

publication date

18 June 2015

0 references

published in

0 references

cites work

5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Conceptualization and measurement of quality of life in dementia: the dementia quality of life instrument (DQoL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Trazodone: a 5-year review of antidepressant efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Prediction of response of chronic depression to imipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: effects on personality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Maintenance therapy for chronic depression. A controlled clinical trial of desipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Maintenance desipramine for dysthymia: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Phenelzine v imipramine in atypical depression. A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Antidepressant specificity in atypical depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Atypical depression, panic attacks, and response to imipramine and phenelzine. A replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Use of pattern analysis to identify true drug response. A replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

The identification and validation of distinct depressive syndromes in a population-based sample of female twins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Tyramine sulfate excretion may be a better predictor of antidepressant response than monoamine oxidase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Viloxazine in the treatment of depressive neurosis: a controlled clinical study with doxepin and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Iprindole in Neurotic Depressed General Practice Patients: A Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Pizotifen as an antidepressant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Baseline characteristics of 10-day placebo washout responders in antidepressant trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Treatment outcome validation of DSM-III depressive subtypes. Clinical usefulness in outpatients with mild to moderate depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Controlled trial of amitriptyline in general practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Drugs in Depressive Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

An evaluation of alprazolam in the treatment of reactive or neurotic (secondary) depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Imipramine and chlordiazepoxide in depressive and anxiety disorders. I. Efficacy in depressed outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Placebo-controlled study of mianserin in depressed outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Effects of ritanserin on sleep disturbances of dysthymic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Depressive Illness in a General Practice. A Demographic Study and a Controlled Trial of Imipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Differential response to chlorpromazine, imipramine, and placebo. A study of subgroups of hospitalized depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Adverse Reactions to Phenelzine: Results of a Nine‐Hospital Depression Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Depression subtypes and response to phenelzine, diazepam, and a placebo. Results of a nine hospital collaborative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Amitriptyline and Trimipramine in Neurotic Depressed Outpatients: A Collaborative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Responses to phenelzine and amitriptyline absence of differential predictors by multiple regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Response to phenelzine and amitriptyline in subtypes of outpatient depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Amantadine in depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Cilobamine in the treatment of atypical depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Isocarboxazid. Efficacy and tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Longitudinal study of the influence of life events and personality status on diagnostic change in three neurotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

The Nottingham study of neurotic disorder. Effect of personality status on response to drug treatment, cognitive therapy and self-help over two years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

The general neurotic syndrome: a coaxial diagnosis of anxiety, depression and personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

The Nottingham study of neurotic disorder: comparison of drug and psychological treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Long-term outcome of hypochondriacal personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Dysthymic disorder: psychopathology of proposed chronic depressive subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Putting trials on trial--the costs and consequences of small trials in depression: a systematic review of methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

The epidemiology of dysthymia in five communities: rates, risks, comorbidity, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

Efficacy of desipramine in depressed outpatients. Response according to research diagnosis criteria diagnoses and severity of illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Imipramine treatment for chronic depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Maintenance Phase Efficacy of Sertraline for Chronic Depression A Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Pipradrol in mild depression: a controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

True and apparent side effects in a controlled trial of chlorpromazine and imipramine in depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Study duration in antidepressant research: advantages of a 12-week trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Social functioning in chronic depression: effect of 6 weeks of antidepressant treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Follow-up assessment of medication-treated dysthymia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

The combination of protriptyline and oxazepam in depressed neurotic general practice patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Nottingham study of neurotic disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Do age of onset and course of illness predict different treatment outcome among DSM IV depressive disorders with atypical features?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Treatment of mild/moderate depressions with Hypericum

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

The treatment of depression in general practice: a comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Prediction of outcome in neurotic disorder: a 5-year prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Are tricyclic antidepressants useful for mild depression? A placebo controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

A Placebo-controlled Study of the Antidepressant Activity of Moclobemide,A New MAO-A Inhibitor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Buspirone therapy in anxious elderly patients: a controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Pharmacotherapy of Dysthymia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

A model for drug use with depressed patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Separate and combined anxiolytic and anti-depressant treatment of mixed anxiety/depression. A double-blind, placebo controlled comparison. Sussex Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Amisulpride versus amineptine and placebo for the treatment of dysthymia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Viloxazine in the treatment of depressive neurosis: a placebo and standard (imipramine) controlled clinical study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

A collaborative study of a new antidepressant, viloxazine, in neurotic and endogenous depressives

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Phenelzine versus imipramine for atypical depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Imipramine and social-vocational adjustment in chronic depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Can mildly depressed outpatients with atypical depression benefit from antidepressants?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Loss of drug effects during continuation therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Further evidence that a placebo response to antidepressants can be identified

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

A placebo controlled evaluation of L-tryptophan in depression in the elderly

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Dysthymia: a randomized study of cognitive marital therapy and antidepressants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Placebo-controlled double-blind study examining the effectiveness of an hypericum preparation in 105 mildly depressed patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Phenelzine and amitriptyline: effects on symptoms of neurotic depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Influence of acetylator phenotype on antidepressant effects of phenelzine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

The Nottingham Study of Neurotic Disorder: influence of cognitive therapists on outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021

Controlled efficacy study of fluoxetine in dysthymia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001130.PUB2

7 January 2021